Plain-English translation of NCT03152058 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing certolizumab, a medication that reduces inflammation in the body, to see if it can help prevent pregnancy loss and complications in women who have antiphospholipid syndrome (APS)—a blood clotting disorder that affects pregnancy. Currently, standard treatment with blood thinners and aspirin prevents complications in only about half of high-risk pregnancies. The hope is that adding this medication will protect more pregnancies by improving blood flow to the placenta.
About 44% of pregnant women with this blood clotting disorder lose their pregnancies or deliver very early despite current standard treatments. Research suggests that inflammation in the placenta is the root cause, and blocking this inflammation might prevent these tragic outcomes.
You likely qualify if…
You likely don't qualify if…
You would receive injections of the medication starting before 9 weeks of pregnancy, with an initial dose followed by doses every other week. The medication would be stopped at about 27 weeks of pregnancy. You would continue taking your standard blood thinner and aspirin throughout. The study involves regular blood tests to check how the medication is working and how your placenta is developing, continuing through your pregnancy.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States
Canada